Lonnel Coats has been steering Lexicon Pharmaceuticals, Inc. since 2014, becoming a noticeable figure in the biotech field. He brings to the table a solid background with a B.S. in public administration from Oakland University and over 18 years of...

Lonnel Coats has been steering Lexicon Pharmaceuticals, Inc. since 2014, becoming a noticeable figure in the biotech field. He brings to the table a solid background with a B.S. in public administration from Oakland University and over 18 years of experience at Eisai, another big player in the pharmaceuticals game. Under his leadership, Lexicon is focused on developing innovative therapies, particularly in chronic diseases like heart failure. In 2023, he earned a total compensation of $4.11 million, reflecting his performance-driven approach. Interestingly, he has been making strategic moves in the stock market, with fluctuations in his investments showcasing the highs and lows of his holdings. Notably, Lonnel announced his retirement effective July 2024, signaling a shift as the company looks to fill his shoes. His time at Lexicon highlights his commitment to advancing medical science and improving patient care.